<h3>领取 TipRanks 高级版 70% 折扣</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，最大化您的投资组合潜力</li>
</ul>
<p>HC Surgical Specialists Ltd ( (SG:1B1) ) 的公告现已发布。</p>
<p>HC Surgical Specialists 报告截至 2025 年 11 月 30 日的六个月收入为 978 万新元，同比略微下降 1.6%，而归属于股东的利润增长了 17.5%，达到 397 万新元，每股收益增加至 2.59 新加坡分。更强的底线主要得益于非经营性收益，包括金融资产公允价值变动的更高收益，以及没有前一年衍生金融工具的公允价值损失和关联企业的视同处置损失，董事会宣布每普通股派发 0.009 新元的中期股息，强调尽管经营表现平平，仍持续回报股东。</p>
<p>(SG:1B1) 股票的最新分析师评级为买入，目标价为 0.50 新元。要查看 HC Surgical Specialists Ltd 股票的完整分析师预测列表，请参见 SG:1B1 股票预测页面。</p>
<p><strong>关于 HC Surgical Specialists Ltd 的更多信息</strong></p>
<p>HC Surgical Specialists Limited 是一家在新加坡上市的医疗集团，专注于医疗和外科服务行业。该公司及其子公司专注于提供专业的外科护理，特别是在新加坡本地市场。</p>
<p><strong>平均交易量：</strong> 44,981</p>
<p><strong>技术情绪信号：</strong> 买入</p>
<p><strong>当前市值：</strong> 5537 万新元</p>
<p>在 TipRanks 的股票分析页面了解更多关于 1B1 股票的信息。</p>

<p>HC Surgical Specialists Ltd 报告称，截至 2025 年 11 月 30 日的六个月内，归属于股东的利润增长了 17.5%，达到 397 万新元，尽管收入略微下降了 1.6%，降至 978 万新元。利润增长主要归因于非运营性收益。公司宣布每股派发中期股息 0.009 新元。分析师对该股票给予 “买入” 评级，目标价为 0.50 新元。HC Surgical Specialists 在新加坡的医疗和外科服务行业运营，市值为 5537 万新元</p>

<h3>Claim 70% Off TipRanks Premium</h3>
<div class="lb-trans"><h3>领取 TipRanks 高级版 70% 折扣</h3>
</div><ul>
<li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions</li>
<li>Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，最大化您的投资组合潜力</li>
</ul>
</div><p>An announcement from HC Surgical Specialists Ltd ( (SG:1B1) ) is now available.</p>
<div class="lb-trans"><p>HC Surgical Specialists Ltd ( (SG:1B1) ) 的公告现已发布。</p>
</div><p>HC Surgical Specialists reported revenue of S$9.78 million for the six months ended 30 November 2025, slightly down 1.6% year-on-year, while profit attributable to shareholders rose 17.5% to S$3.97 million and earnings per share increased to 2.59 Singapore cents. The stronger bottom line was driven mainly by non-operational gains, including a higher fair value gain on financial assets at fair value through profit or loss and the absence of prior-year fair value losses on derivative financial instruments and losses from deemed disposal in an associate, and the board declared an interim dividend of S$0.009 per ordinary share, underscoring continued shareholder returns despite flat operating performance.</p>
<div class="lb-trans"><p>HC Surgical Specialists 报告截至 2025 年 11 月 30 日的六个月收入为 978 万新元，同比略微下降 1.6%，而归属于股东的利润增长了 17.5%，达到 397 万新元，每股收益增加至 2.59 新加坡分。更强的底线主要得益于非经营性收益，包括金融资产公允价值变动的更高收益，以及没有前一年衍生金融工具的公允价值损失和关联企业的视同处置损失，董事会宣布每普通股派发 0.009 新元的中期股息，强调尽管经营表现平平，仍持续回报股东。</p>
</div><p>The most recent analyst rating on (SG:1B1) stock is a Buy with a S$0.50 price target. To see the full list of analyst forecasts on HC Surgical Specialists Ltd stock, see the SG:1B1 Stock Forecast page.</p>
<div class="lb-trans"><p>(SG:1B1) 股票的最新分析师评级为买入，目标价为 0.50 新元。要查看 HC Surgical Specialists Ltd 股票的完整分析师预测列表，请参见 SG:1B1 股票预测页面。</p>
</div><p><strong>More about HC Surgical Specialists Ltd</strong></p>
<div class="lb-trans"><p><strong>关于 HC Surgical Specialists Ltd 的更多信息</strong></p>
</div><p>HC Surgical Specialists Limited is a Catalist-listed healthcare group in Singapore that operates in the medical and surgical services industry. The company, together with its subsidiaries, focuses on providing specialist surgical care, particularly in the local Singapore market.</p>
<div class="lb-trans"><p>HC Surgical Specialists Limited 是一家在新加坡上市的医疗集团，专注于医疗和外科服务行业。该公司及其子公司专注于提供专业的外科护理，特别是在新加坡本地市场。</p>
</div><p><strong>Average Trading Volume:</strong> 44,981</p>
<div class="lb-trans"><p><strong>平均交易量：</strong> 44,981</p>
</div><p><strong>Technical Sentiment Signal:</strong> Buy</p>
<div class="lb-trans"><p><strong>技术情绪信号：</strong> 买入</p>
</div><p><strong>Current Market Cap:</strong> S$55.37M</p>
<div class="lb-trans"><p><strong>当前市值：</strong> 5537 万新元</p>
</div><p>Learn more about 1B1 stock on TipRanks’ Stock Analysis page.</p>
<div class="lb-trans"><p>在 TipRanks 的股票分析页面了解更多关于 1B1 股票的信息。</p>
</div>

HC Surgical Specialists 因投资收益增加提升了半年利润，并宣布了中期股息